Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL ...

Ligand Pharmaceuticals stock opened at $106.22 on Tuesday. The firm has a 50-day moving average price of $114.25 and a 200-day moving average price of $111.77. The firm has a market capitalization ...

Ligand Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $1.27 EPS, expectations were $1.37. Melanie Herman: Good morning everyone and welcome to Ligand’s Fourth ...

(RTTNews) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal 2025 forecast.

The latest price target for Ligand Pharmaceuticals (NASDAQ:LGND) was reported by Benchmark on December 23, 2024. The analyst firm set a price target for $135.00 expecting LGND to rise to within 12 ...

RBC Capital analyst Douglas Miehm reiterated a Buy rating on Ligand Pharma (LGND – Research Report) yesterday and set a price target of $155.00. The company’s shares closed last Friday at $122.23.

Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2024, and provided an ...

JUPITER, Fla. (AP) — JUPITER, Fla. (AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $31.1 million in its fourth quarter. On a per-share basis, the Jupiter, Florida ...

Arizona State Retirement System increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free ...

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo ...